Shepherd Hailey M, Terada Yuriko, Takahashi Tsuyoshi, Pasque Michael K, Kulkarni Hrishikesh S, Guillamet Rodrigo Vazquez, Witt Chad A, Nava Ruben G, Puri Varun, Kreisel Daniel, Patterson G Alexander, Hachem Ramsey R
Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
Transplant Proc. 2022 Oct;54(8):2313-2316. doi: 10.1016/j.transproceed.2022.07.010. Epub 2022 Sep 6.
Acute interstitial pneumonia (AIP), also known as Hamman-Rich syndrome, is a rare and rapidly progressive idiopathic interstitial lung disease with a high mortality rate. Treatment is limited to supportive care and empirical high-dose steroids; however, outcomes are generally poor. There are few reports of lung transplantation (LTx) in patients with AIP.
We retrospectively identified patients with AIP among those who underwent LTx at our center between January 2008 and December 2020.
During the study period, 4 patients with AIP underwent bilateral LTx: 3 men and 1 woman, between 30 and 57 years of age. The lung allocation score ranged between 71 and 89. Of the 4 patients, 2 needed extracorporeal membrane oxygenation and mechanical ventilation (MV) and 1 needed MV preoperatively. Time of onset to transplant ranged from 1 to 3 months. None of the patients had primary graft dysfunction after LTx; 2 had acute cellular rejection and 1 had chronic lung allograft dysfunction. The 4 patients are alive with survival ranging between 1 and 12 years after LTx.
AIP should be considered in patients with acute respiratory failure without a clear etiology. Our study showed that LTx led to good outcomes and should be considered as a treatment option in appropriate candidates.
急性间质性肺炎(AIP),也称为Hamman-Rich综合征,是一种罕见且进展迅速的特发性间质性肺疾病,死亡率高。治疗仅限于支持治疗和经验性大剂量使用类固醇;然而,总体预后通常较差。关于AIP患者肺移植(LTx)的报道很少。
我们回顾性地在2008年1月至2020年12月期间在本中心接受LTx的患者中识别出AIP患者。
在研究期间,4例AIP患者接受了双侧LTx:3例男性和1例女性,年龄在30至57岁之间。肺分配评分在71至89之间。4例患者中,2例需要体外膜肺氧合和机械通气(MV),1例术前需要MV。从发病到移植的时间为1至3个月。LTx后无患者发生原发性移植物功能障碍;2例发生急性细胞排斥反应,1例发生慢性肺移植功能障碍。4例患者存活,LTx后存活时间为1至12年。
对于病因不明的急性呼吸衰竭患者应考虑AIP。我们的研究表明,LTx可带来良好的预后,应将其视为合适候选者的一种治疗选择。